<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        90-119-98
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1998
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        INFLABAN 12.5MG SUPP.
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DICLOFENAC SODIUM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        12.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Rectal use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Suppository
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store below 30°C , Protect from light and moisture
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        5.15
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="APM" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            APM
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 612]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Abdulrehman Algosaibi G.T.C.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            APM
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M01AB05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Diclofenac &nbsp;sodium, &nbsp;the active ingredient in INFLA-BAN suppositories, is one of a group of medicines called non-steroidal anti-inflammatory drugs &nbsp;(NSAIDs).</p><p>NSAIDs reduce pain and inflammation.</p><ul><li>INFLA-BAN suppositories relieve pain, reduce swelling and ease inflammation &nbsp;in conditions affecting the joints, muscles and tendons including:</li></ul><p style="margin-left:40px">- Rheumatoid arthritis, osteoarthritis, acute gout, ankylosing spondylitis.</p><p style="margin-left:40px">- Backache, sprains and strains, soft tissue sports injuries, frozen shoulder, dislocations and fractures.</p><p style="margin-left:40px">- Tendonitis, tenosynovitis, bursitis.</p><ul><li>They are also used to treat pain and inflammation &nbsp;associated with dental &nbsp;and minor surgery.</li><li>In children aged 1 to 12 INFLA-BAN suppositories 12.5 are used to treat juvenile chronic arthritis.</li><li>In children aged over 6 they can also be used alone, &nbsp;or in combination with other painkillers, for the short term&nbsp;treatment of any pain experienced after an operation.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take INFLA-BAN</strong></p><p>Some people must not take INFLA-BAN suppositories. Talk to your doctor if:</p><ul><li>You think you may be allergic to diclofenac sodium, &nbsp;aspirin, &nbsp;ibuprofen &nbsp;or any other NSAID, or to any of the other ingredients of INFLA-BAN suppositories. Signs &nbsp;of a hypersensitivity reaction include swelling of the face and mouth (angioedema), breathing problems, runny&nbsp;nose, skin rash &nbsp;or any other allergic type.</li><li>You have &nbsp;now, or have &nbsp;ever had, &nbsp;a stomach (gastric) &nbsp;or duodenal (peptic) ulcer, or bleeding in the digestive tract (this&nbsp;can include blood in vomit, bleeding when emptying, &nbsp;fresh blood in faeces or black, tarry faeces).</li><li>You have &nbsp;had stomach or bowel problems after you have &nbsp;taken &nbsp;other NSAIDs.</li><li>You have &nbsp;severe heart, &nbsp;kidney or liver failure.</li><li>If you have &nbsp;established heart &nbsp;disease and/or &nbsp;cerebrovascular disease e.g. if you have &nbsp;had a heart &nbsp;attack, &nbsp;stroke,&nbsp;mini-stroke &nbsp;(TIA) or blockages to blood vessels to the heart &nbsp;or brain or an operation to clear or bypass blockages</li><li>If you have &nbsp;or have &nbsp;had problems with your blood circulation (peripheral arterial disease)</li><li>You are more than six months pregnant</li><li>You suffer from ineffectual &nbsp;straining &nbsp;to empty the bowels, &nbsp;diarrhoea or rectal bleeding</li></ul><p><strong>T</strong><strong>ake special care with INFLA-BAN</strong></p><p>You should &nbsp;also ask yourself these questions before &nbsp;taking INFLA-BAN suppositories:</p><ul><li>Do you suffer from any stomach or bowel disorders including ulcerative colitis or Crohn&rsquo;s disease?</li><li>Do you have &nbsp;kidney or liver problems, or are you elderly?</li><li>Do you have &nbsp;a condition called porphyria?</li><li>Do you suffer from any blood or bleeding disorder? If you do, your doctor may ask you to go for regular check-ups while you are using these suppositories.</li><li>Have you ever had asthma?</li><li>Are you breast-feeding?</li><li style="text-align:center">Do you have &nbsp;angina, blood clots, high blood pressure, raised cholesterol or raised triglycerides?</li><li>Do you have &nbsp;heart &nbsp;problems, or have &nbsp;you had a stroke, &nbsp;or do you think you might be at risk of these conditions (for&nbsp;example, if you have &nbsp;high blood pressure, diabetes or high cholesterol or are a smoker)?</li><li>Do you have &nbsp;diabetes?</li><li>Do you smoke?</li><li>Do you have &nbsp;Lupus (SLE) or any similar condition?</li></ul><p><strong>If the answer to any of these questions is YES, discuss your treatment with your doctor or pharmacist because INFLA-BAN suppositories might not be the right medicine for you.</strong></p><p><strong>T</strong><strong>aking other medicines, herbal or dietary supplements</strong></p><p>Some medicines can interfere &nbsp;with your treatment. Tell your doctor or pharmacist if you are taking any of the following:</p><ul><li>Medicines to treat diabetes.</li><li>Anticoagulants (blood thinning tablets like warfarin).</li><li>Diuretics (water tablets).</li><li>Lithium (used to treat some mental &nbsp;problems).</li><li>Methotrexate (for some inflammatory &nbsp;diseases and some cancers).</li><li>Ciclosporin &nbsp;and tacrolimus &nbsp;(used to treat some inflammatory &nbsp;diseases and after transplants).</li><li>Trimethoprim &nbsp;(a medicine used to prevent or treat urinary tract infections).</li><li>Quinolone &nbsp;antibiotics &nbsp;(for infections).</li><li>Any other NSAID or COX-2 (cyclo-oxgenase-2) inhibitor, for example aspirin or ibuprofen.</li><li>Mifepristone &nbsp;(a medicine used to terminate pregnancy).</li><li>Cardiac glycosides (for example digoxin), used to treat heart &nbsp;problems.</li><li>Medicines known as SSRIs used to treat depression.</li><li>Oral steroids (an anti-inflammatory drug).</li><li>Medicines used to treat heart &nbsp;conditions or high blood pressure, for example beta &nbsp;blockers or ACE inhibitors.</li><li>Voriconazole (a medicine used to treat fungal infections).</li><li>Phenytoin (a medicine used to treat seizures)</li><li>Colestipol/cholestyramine (used to lower cholesterol).</li></ul><p><strong>Always tell your doctor or pharmacist about all the medicines you are taking. This means medicines you have bought yourself as well as medicines on prescription from your doctor.</strong></p><p><strong>Pregnancy and breast feeding</strong></p><p>Are you pregnant or planning &nbsp;to become pregnant? Although not common, abnormalities have &nbsp;been reported in babies whose mothers have &nbsp;taken &nbsp;NSAIDs during pregnancy. You should &nbsp;not take INFLA-BAN suppositories during the last 3 months of pregnancy as it may affect the baby&rsquo;s circulation.</p><p>Are you trying for a baby? Taking INFLA-BAN suppositories may make &nbsp;it more difficult to conceive. You should &nbsp;talk to your doctor if you are planning &nbsp;to become pregnant, or if you have &nbsp;problems getting pregnant.</p><p>Please ask your doctor, &nbsp;healthcare provider or pharmacist for advice &nbsp;before &nbsp;taking any medicine.</p><p><strong>Driving and using machines</strong></p><p>Very occasionally people have &nbsp;reported that INFLA-BAN suppositories have &nbsp;made them feel dizzy, tired or sleepy.</p><p>Problems with eyesight have &nbsp;also been reported. If you are affected in this way, you should &nbsp;not drive or operate machinery.</p><p><strong>Important information about some of the ingredients of INFLA-BAN</strong></p><p>INFLA-BAN contains sodium. &nbsp;This should &nbsp;be taken &nbsp;into consideration if you are on a controlled &nbsp;sodium &nbsp;diet.</p><p><strong>Other special warnings</strong></p><ul><li>You should &nbsp;take the lowest dose of INFLA-BAN Suppositories for the shortest possible time, particularly if you are&nbsp;underweight or elderly.</li><li>There &nbsp;is a small increased risk of heart &nbsp;attack &nbsp;or stroke &nbsp;when you are taking any medicine like INFLA-BAN. The risk is higher if you are taking high doses for a long time. Always follow the doctor&rsquo;s instructions on how much to take and&nbsp;how long to take it for.</li><li>Whilst you are taking these medicines your doctor may want to give you a check-up from time to time.</li><li>If you have &nbsp;a history of stomach problems when you are taking NSAIDs, particularly if you are elderly, you must tell&nbsp;your doctor straight &nbsp;away if you notice any unusual symptoms.</li><li>Because it is an anti-inflammatory medicine, INFLA-BAN may reduce the symptoms of infection, for example,&nbsp;headache and high temperature. If you feel unwell and need to see a doctor, &nbsp;remember to tell him or her that you are taking INFLA-BAN.</li><li><strong>INFLA-BAN suppositories 50 mg and 100 mg are not suitable for children.</strong></li><li><strong>INFLA-BAN suppositories 12.5 mg are not used for adults.</strong></li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The doctor will tell you how many INFLA-BAN suppositories to take and when to take them. Always follow his/her&nbsp;instructions carefully. The dose will be on the pharmacist&rsquo;s label. Check &nbsp;the label carefully. If you are not sure, ask your doctor or pharmacist. Keep taking your suppositories for as long as you have &nbsp;been told, unless you have &nbsp;any problems.</p><p>In that case, check &nbsp;with your doctor.&nbsp;</p><p>Suppositories are designed for insertion &nbsp;into the back passage (rectum).</p><p><strong>Never take them by mouth.</strong></p><p>The doctor may also prescribe another drug to protect &nbsp;the stomach to be taken &nbsp;at the same time, particularly if you have had stomach problems before, or if you are elderly, or taking certain &nbsp;other drugs &nbsp;as well.</p><p><strong>Adults</strong></p><p>INFLA-BAN suppositories are normally inserted one, two or three times a day up to a maximum total daily dose of 150 mg. The number of suppositories you need will depend on the strength which the doctor has given you.</p><p><strong>Elderly</strong></p><p>Your doctor may advise you to take a dose that is lower than the usual &nbsp;adult dose if you are elderly. Your doctor may also&nbsp;want to check &nbsp;closely that the INFLA-BAN suppositories are not affecting your stomach, particularly during the first 4&nbsp;weeks that you are using the suppositories.</p><p><strong>Children</strong></p><p><strong>For the treatment &nbsp;of chronic juvenile arthritis in children aged 1 to 12:</strong></p><p>Doses vary with age, &nbsp;but are usually between 1 and 3 mg/kg body weight every day divided into 2 or 3 doses.</p><p><strong>For the treatment &nbsp;of post-operative pain in children aged 6 and over:</strong></p><p>Doses vary with age, &nbsp;but are usually between 1 and 2 mg/kg body weight per day divided into 2 or 3 doses for no more than 4 days.</p><p>Your child&rsquo;s doctor will work out the dose that is suitable for your child and will tell you how many INFLA-BAN suppositories to use &nbsp;and how often. Follow his/her &nbsp;instructions carefully. If you are not sure &nbsp;about &nbsp;the dose, check &nbsp;with your doctor or pharmacist.</p><p>The doctor may also prescribe another drug to protect &nbsp;the stomach to be taken &nbsp;at the same time, particularly if you have had stomach problems before, or if you are elderly, or taking certain &nbsp;other drugs &nbsp;as well.</p><p><strong>How to insert the suppositories</strong></p><p>1. &nbsp;Empty your bowels &nbsp;before &nbsp;inserting &nbsp;a suppository.</p><p>2. &nbsp;Wash &nbsp;your hands.</p><p>3. &nbsp;Take out the strip of suppositories and tear off one along the perforation.</p><p>4. &nbsp;Then take the suppository out of the plastic wrapping &nbsp;by pulling back the loose &nbsp;end.</p><p><img alt="" width="255" height="141" src="data:image/png;base64,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" /></p><p>5. &nbsp;Lie on one side with your knees pulled up towards your chest.</p><p>6. &nbsp;Gently push &nbsp;the suppository pointed &nbsp;end first into your back passage (rectum) &nbsp;with your finger. Push the suppository&nbsp;in as far as possible as shown &nbsp;in the diagram.</p><p><img alt="" width="256" height="114" src="data:image/png;base64,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" /></p><p>7. &nbsp;Lower your legs and, &nbsp;if possible, stay still for a few minutes.</p><p>8. &nbsp;If you feel as if you need to push &nbsp;the suppository out, try to resist &nbsp;this by lying still with your buttocks pressed&nbsp;together. It is important &nbsp;to keep &nbsp;the suppository in the rectum &nbsp;to allow it to melt and the medicine to be absorbed.</p><p>Pushing the suppository high into the rectum &nbsp;with your finger will help to reduce this feeling.</p><p>9. &nbsp;Wash &nbsp;your hands.</p><p>The procedure is the same for a child. Once &nbsp;they have &nbsp;emptied their bowels, &nbsp;get them to lie down on their front or side.</p><p>Gently push &nbsp;the suppository into the child&rsquo;s back passage until it disappears. Try and stop the child moving around for a few minutes to reduce the risk of the suppository coming out.</p><p><strong>If you take more INFLA-BAN than you should</strong></p><p>You should &nbsp;not take more than 150 mg in one day if you are an adult. Children should &nbsp;not take more than the dose that is prescribed by their doctor. &nbsp;If you accidentally use &nbsp;too many suppositories or use &nbsp;them too often, tell your doctor or go&nbsp;to your nearest casualty department straight &nbsp;away.</p><p><strong>If you forget to take INFLA-BAN</strong></p><p>If you forget to use &nbsp;a suppository, do not worry. Use one as soon &nbsp;as you remember. If it is nearly time for your next dose though, just take the next dose and forget about &nbsp;the one you missed. Do not double &nbsp;up the next dose to make &nbsp;up for the&nbsp;one you missed. Do not insert 2 suppositories at the same time. The total dose should &nbsp;not be more than 150 mg each day if you are an adult.</p><p><strong>Children should not take more than the dose that is prescribed by their doctor.</strong></p><p>If you have &nbsp;any further questions on the use &nbsp;of this product, &nbsp;ask your doctor, &nbsp;healthcare provider or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>INFLA-BAN suppositories are suitable for most people, but, like all medicines, they can sometimes cause side effects.</p><p><strong>Some side effects can be serious</strong></p><p><strong>Stop &nbsp;taking INFLA-BAN and tell your doctor straight away if you notice:</strong></p><ul><li>Stomach pain, indigestion, heartburn, wind, nausea (feeling sick) or vomiting (being sick).</li><li>Any sign of bleeding in the stomach or intestine, for example, when emptying &nbsp;your bowels, &nbsp;blood in vomit or black,&nbsp;tarry faeces.</li><li>Allergic reactions which can include skin rash, itching, bruising, &nbsp;painful red areas, peeling &nbsp;or blistering.</li><li>Wheezing or shortness of breath (bronchospasm).</li><li>Swollen face, &nbsp;lips, hands or fingers.</li><li>Yellowing of your skin or the whites of your eyes.</li><li>Persistent sore &nbsp;throat or high temperature.</li><li>An unexpected change in the amount of urine produced and/or &nbsp;its appearance.</li></ul><p>If you notice that you are bruising more easily than usual &nbsp;or have &nbsp;frequent sore &nbsp;throats or infections, &nbsp;tell your doctor.</p><p>INFLA-BAN suppositories may also occasionally cause itching or burning in your back passage or make &nbsp;any haemorrhoids (piles) worse.</p><p>&nbsp;</p><p><strong>The side effects listed below have also been reported.</strong></p><p><strong>Common side effects (These </strong><strong>may affect &nbsp;between 1 and 10 in every &nbsp;100 patients):</strong></p><ul><li>Stomach pain, heartburn, nausea, vomiting, diarrhoea, indigestion, wind, loss of appetite.</li><li>Headache, dizziness, vertigo.</li><li>Skin rash &nbsp;or spots.</li><li>Raised levels of liver enzymes in the blood.</li><li>Irritation where &nbsp;the suppository is inserted.</li></ul><p><strong>Rare side effects (These may affect &nbsp;between 1 in every &nbsp;1000 to 1 in every &nbsp;10,000 patients):</strong></p><ul><li>Stomach ulcers &nbsp;or bleeding (there &nbsp;have &nbsp;been very rare reported cases resulting &nbsp;in death, particularly in the elderly)</li><li>Gastritis &nbsp;(inflammation, &nbsp;irritation or swelling of the&nbsp;stomach lining)</li><li>Vomiting blood</li><li>Diarrhoea with blood in it or bleeding from the back passage</li><li>Black, tarry faeces or stools</li><li>Drowsiness, tiredness</li><li>Hypotension (low blood pressure, symptoms of which may include faintness, giddiness or light headedness)</li><li>Skin rash &nbsp;and itching</li><li>Fluid retention, symptoms of which include swollen ankles</li><li>Liver function disorders, including hepatitis and jaundice</li></ul><p><strong>V</strong><strong>ery rare side effects (These may affect &nbsp;less than 1 in every &nbsp;10,000 patients):</strong></p><p><strong>Effects </strong><strong>on the nervous system:</strong></p><p>Tingling or numbness in the fingers, &nbsp;tremor, &nbsp;visual disturbances such &nbsp;as blurred vision, blurred or double &nbsp;vision, hearing&nbsp;loss or impairment, tinnitus (ringing in the ears), sleeplessness, nightmares, mood changes, depression, anxiety, &nbsp;mental disorders, disorientation and loss of memory, &nbsp;fits, headaches together with a dislike of bright lights, fever and a stiff neck, disturbances in sensation.</p><p><strong>Effects </strong><strong>on the stomach and digestive system:</strong></p><p>Constipation, inflammation &nbsp;of the tongue, mouth ulcers, &nbsp;inflammation &nbsp;of the inside of the mouth or lips, taste changes,&nbsp;lower gut disorders (including inflammation &nbsp;of the colon or worsening of ulcerative colitis or Crohn&rsquo;s disease).</p><p><strong>Effects </strong><strong>on the heart, chest or blood:</strong></p><p>Palpitations (fast or irregular heart &nbsp;beat), &nbsp;chest pain, hypertension (high blood pressure), inflammation &nbsp;of blood vessels (vasculitis), &nbsp;inflammation &nbsp;of the lung (pneumonitis) heart &nbsp;disorders,including congestive heart &nbsp;failure or heart &nbsp;attack,&nbsp;blood disorders (including anaemia).</p><p><strong>Effects </strong><strong>on the liver or kidneys:</strong></p><p>Kidney or severe liver disorders including liver failure, presence of blood or protein in the urine.</p><p><strong>Effects </strong><strong>on skin or hair:</strong></p><p>Serious skin rashes including Stevens-Johnson syndrome and Lyell&rsquo;s syndrome and other skin rashes which may be made worse &nbsp;by exposure to sunlight.</p><p>Hair loss.</p><p><strong>Other side effects that have &nbsp;also been reported include:</strong></p><p>Inflammation &nbsp;of the pancreas, impotence. Facial swelling, inflammation &nbsp;of the lining of the brain (meningitis), &nbsp;stroke, throat disorders, confusion, hallucinations, malaise (general feeling of discomfort), &nbsp;inflammation &nbsp;of the nerves of the eye.</p><p><strong>Do not be alarmed by this list - most people take INFLA-BAN suppositories without any problems.</strong></p><p><strong>If any of the symptoms become troublesome or if you notice anything else not mentioned here, please go and&nbsp;see your doctor. The doctor may want to give you a different medicine.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>Keep out of the reach and sight of children.</li><li>Store &nbsp;below 30&deg;C, away from light.</li><li>Do not take INFLA-BAN after the expiry date &nbsp;which is printed on the outside of the pack. The expiry date &nbsp;refers &nbsp;to&nbsp;the last day of that month.</li><li>Do not use &nbsp;INFLA-BAN &nbsp;if you notice visible signs &nbsp;of deterioration.</li><li>If your doctor tells you to stop taking the suppositories, please take any unused suppositories back to your pharmacist to be destroyed. Do not throw them away with your normal household water or waste. This will help to&nbsp;protect &nbsp;the environment.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance in each suppository is 12.5, 50 or 100 mg diclofenac sodium.</p><p>The other ingredients are suppocire NBL waxy solid and witepsol H-15 hard fat.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                INFLA-BAN 12.5 mg suppositories are off-white to creamy white, torpedo shape. They are packaged in opaque white plastic laminated PVC/PE  foil.
INFLA-BAN 50 mg suppositories are white to yellowish white, torpedo shape. They are packaged in opaque white plastic laminated PVC/PE  foil. Each  pack contains 10 suppositories.
INFLA-BAN 100 mg suppositories are white to yellowish white, torpedo shape. They are packaged in opaque white plastic laminated PVC/PE  foil. Each  pack contains 5  suppositories.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorization Holder and Manufacturer </strong></p><p>The Arab Pharmaceutical Manufacturing Co. Ltd. (APM)</p><p>P.O.Box &nbsp;42</p><p>Sult-Jordan</p><p>Tel: (+962-5)3492200</p><p>Fax: (+962-5)3492203</p><p>Website: www.apm.com.jo</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet  was  last approved in 05/2014; version number  v1.1.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ينتمي ديكلوفيناك الصوديوم، المادة الفعالة في تحاميل إنفلابان، إلى المجموعة الدوائية التي تسمى مضادات الالتهاب غير الستيرويدية.<br />تخفض مضادات الالتهاب غير الستيرويدية الألم والالتهاب.</p><ul><li>تخفف تحاميل إنفلابان من الألم و التورم و الالتهاب في الأمراض التي تصيب المفاصل والعضلات والأوتار بما في ذلك:</li></ul><p>&minus; التهاب المفاصل الروماتويدي، الفصال العظمي، النقرس الحاد، التهاب الفقار&nbsp; المقسّط.<br />&minus; آلام الظهر، والالتواءات والإجهاد، الإصابات الرياضية للأنسجة اللينة، التهاب المحفظة اللاصق، والخلع والكسور.<br />&minus;&nbsp;التهاب الأوتار، التهاب زليل الوتر، التهاب الجراب.</p><ul><li>كما أنها تستخدم لعلاج الألم والالتهابات المرتبطة في العمليات الجراحية الصغرى وجراحة الأسنان.</li><li>تستخدم تحاميل إنفلابان 12.5 ملغم لعلاج التهاب المفاصل اليفعي المزمن لدى الأطفال الذين تتراوح أعمارهم من 1- 12 سنة.</li><li>يمكن أن تستخدم أيضا لوحدها أو مقترنة مع مسكنات الألم الأخرى لدى الأطفال الذين تزيد أعمارهم عن 6 سنوات، من أجل العلاج على المدى القصير لأي ألم يعانى منه بعد عملية جراحية.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>موانع استعمال إنفلابان:</strong><br />يجب عدم استخدام تحاميل انفلابان لدى بعض الأشخاص.<br /><strong>أخبر طبيبك إذا:</strong></p><ul><li dir="rtl">كنت تعتقد أنك تعاني من حساسية لديكلوفيناك الصوديوم والأسبرين والأيبوبروفين أو لأي من مضادات الالتهاب غير الستيرويدية ، أو لإحدى المواد المستخدمة في تركيبة تحاميل إنفلابان. (إنها مدرجة في نهاية النشرة). تشمل علامات ردود الفعل التحسسية: تورم في الوجه والفم (الوذمة الوعائية)، المشاكل التنفسية، وسيلان الأنف والطفح الجلدي أوأي نوع آخر من أنواع الحساسية.</li><li dir="rtl">كانت لديك الآن أو عانيت في السابق من قرحة في المعدة (معدية) أو الإثنى عشر (هضمية) أو نزيف في الجهاز الهضمي (ويمكن أن يشمل هذا: دم في القيء، ونزيف عند الإفراغ، دم نقي في البراز أو براز أسود، أو براز قطراني).</li><li dir="rtl">كانت لديك سابقا مشاكل في المعدة أو الأمعاء بعد تناول مضادات الالتهاب غير الستيرويدية الأخرى.</li><li dir="rtl">كان لديك قصور في القلب والكلى أو الكبد.</li><li dir="rtl">إذا ظهر لديك مرض في القلب و / أو في الأوعية الدماغية مثل نوبة قلبية والسكتة الدماغية والسكتة الدماغية الصغيرة (النوبة الإقفارية العابرة) أو انسداد الأوعية الدموية في القلب أو الدماغ أو عملية لإزالة أو مجازة الانسدادات في الأوعية.</li><li dir="rtl">كانت لديك الآن أو سابقا مشاكل في الدورة الدموية (مرض الشريان المحيطي).</li><li dir="rtl">كنت حاملا منذ أكثر من ستة أشهر.</li><li dir="rtl">كنت تعاني من إجهاد غير فعال لإفراغ الأمعاء، الإسهال أو النزف في المستقيم.</li></ul><p><strong>الاحتياطات عند استخدام إنفلابان</strong><br />يجب أن تسأل نفسك هذه الأسئلة قبل استخدام تحاميل إنفلابان:</p><ul><li>هل تعاني من اضطرابات في المعدة أو الأمعاء بما في ذلك التهاب القولون التقرحي أو مرض كرون؟</li><li>هل لديك مشاكل في الكلى أو في الكبد أو هل أنت مسن؟</li><li>هل لديك مرض يسمى البرفيرية؟</li><li>هل تعاني من اضطرابات نزفية أو في الدم؟ إذا كان الأمر كذلك، قد يطلب منك طبيبك إجراء فحوصات منتظمة أثناء تناولك لهذه التحاميل.</li><li>هل كان لديك مرض الربو؟</li><li>هل أنت مرضعة؟</li><li>هل لديك ذبحة صدرية، وتجلط الدم، وارتفاع في ضغط الدم أوالكوليستيرول أو الدهون ثلاثية الغليسريد؟</li><li>هل لديك مشاكل في القلب أو قد أصبت بسكتة دماغية أو تعتقد بأنك في خطر الإصابة بهذه الأمراض (على سبيل المثال، إذا كان لديك ارتفاع في ضغط الدم أو مرض السكري أو ارتفاع في لكوليستيرول الدم أو إذا كنت مدخنا؟)</li><li>هل لديك مرض السكري؟</li><li>هل تدخن؟</li><li>هل لديك الذئبة (الذئبة الحمامية المجموعية) أو أي مرض مشابه؟</li></ul><p><strong>إذا كان الجواب نعم على أية من هذه الأسئلة، ناقش العلاج مع طبيبك أو الصيدلي لأن إنفلابان قد لا يكون الدواء المناسب لك.<br />التداخلات الدوائية مع الأدوية الأخرى أو الأعشاب أو المكملات الغذائية</strong><br />يمكن أن تتداخل بعض الأدوية مع دوائك. ويجب إخبار طبيبك أو الصيدلي إذا كنت تأخذ أيا من الأدوية التالية:</p><ul><li>أدوية لمعالجة مرض السكري.</li><li>مضادات التجلط (أقراص تمييع الدم مثل الوارفارين).</li><li>مدرات البول (أقراص مدرة للماء).</li><li>الليثيوم (الذي يستخدم في علاج بعض المشاكل النفسية).</li><li>الميثوتريكسات (من أجل بعض الأمراض الالتهابية وبعض أنواع السرطان) .</li><li>السيكلوسبورين والتاكروليموس (التي تستخدم من أجل علاج بعض الأمراض الالتهابية وبعد عمليات زرع الأعضاء).</li><li>التريميثوبريم (دواء يستخدم من أجل منع أو علاج التهابات المسالك البولية).</li><li>الكوينولون من المضادات الحيوية (من أجل الأمراض المعدية).</li><li>أي دواء آخر من مجموعة مضادات الالتهاب غير الستيرويدية أومثبطات كوكس- 2 (سيكلوأكسجيناز- 2)، على سبيل المثال الأسبرين أو الأيبوبروفين.</li><li>ميفيبريستون (دواء يستخدم من أجل الإجهاض).</li><li>الغليكوزيدات القلبية (على سبيل المثال الديجوكسين)، التي تستخدم في علاج مشاكل القلب.</li><li>الأدوية المعروفة باسم مثبطات إعادة امتصاص السيروتونين الانتقائية التي تستخدم في علاج الاكتئاب.</li><li>الستيرويدات الفموية (دواء مضاد للالتهابات).</li><li>الأدوية المستخدمة من أجل علاج أمراض القلب أو ارتفاع ضغط الدم، على سبيل المثال حاصرات بيتا أو مثبطات الإنزيم المحول للأنجيوتنسين.</li><li>فوريكونازول (دواء يستخدم في علاج الالتهابات الفطرية).</li><li>فينيتوين (دواء يستخدم في علاج النوبات).</li><li>كوليستيبول / كوليسترامين (التي تستخدم من أجل خفض الكولسترول).</li></ul><p><strong>أخبر طبيبك أو الصيدلي دائما عن جميع الأدوية التي تتناولها. بما فيها الأدوية التي قمت بشرائها بدون وصفة طبية أو بناءا على وصفة طبية من طبيبك.<br />الحمل والرضاعة</strong><br />هل أنت حاملا أو تخططين لذلك؟ على الرغم من أنه ليس شائعا، قد تم الإبلاغ عن شذوذ لدى المواليد الذين تناولت أمهاتهم مضادات الالتهاب غير الستيرويدية أثناء الحمل. ويجب عدم تناول تحاميل إنفلابان خلال الثلاثة أشهر الأخيرة من الحمل بما أنه قد يؤثر على الدورة الدموية للمولود.<br />هل تحاولين الإنجاب؟ قد يصعب تناول إنفلابان من حدوث الحمل. ويرجى التحدث إلى طبيبك إذا كنت تخططين للحمل أو إذا كانت لديك مشاكل في حدوث الحمل.<br />يرجى استشارة طبيبك أو مقدم الرعاية الصحية أو الصيدلي قبل تناول أي دواء.<br /><strong>تأثير إنفلابان على القيادة واستخدام الآلات</strong><br />قد تم الإبلاغ في حالات نادرة جدا، أن تحاميل إنفلابان تسبب الدوار، والتعب أو النعاس. كما تم الإبلاغ عن مشاكل في الرؤية. إذا كنت تعاني من هذه الأعراض، يجب أن لا تقم بالقيادة أو تشغيل الآلات.<br /><strong>معلومات هامة حول بعض مكونات إنفلابان</strong><br />يحتوي إنفلابان على الصوديوم. ينبغي أخذ هذا بعين الاعتبار إذا كنت تتبع نظام غذائي مضبوط الصوديوم.</p><p><strong>تحذيرات خاصة أخرى</strong></p><ul><li>ينبغي أن تأخذ أقل جرعة من تحاميل إنفلابان لأقصر فترة ممكنة، بالأخص إذا كنت تعاني من نقص الوزن أو كنت من كبار السن.</li><li>هناك زيادة طفيفة في خطر حدوث النوبة القلبية أو السكتة عندما تأخذ أي دواء مثل إنفلابان. ويزداد الخطر إذا كنت تأخذ جرعات عالية لفترة طويلة. اتبع دائما تعليمات الطبيب في عدد المرات والفترة الزمنية التي يجب أن تأخذه فيها.</li><li>في أثناء تناولك لهذه الأدوية قد يرغب طبيبك في إجراء فحص من وقت لآخر.</li><li>إذا كانت لديك سوابق من مشاكل في المعدة عند تناولك مضادات الالتهاب غير الستيرويدية، بالأخص إذا كنت من كبار السن، يجب إخبار طبيبك فورا إذا لاحظت أي أعراض غير عادية.</li><li>بما أنه دواء مضاد للالتهابات، قد يقلل إنفلابان من أعراض الالتهاب، على سبيل المثال، الصداع وارتفاع درجة الحرارة. إذا كنت تشعر بتوعك وبحاجة إلى مراجعة الطبيب، تذكر أن تخبره أو تخبرها أنك تأخذ إنفلابان.</li><li><strong>إن تحاميل إنفلابان 50 ملغم و 100 ملغم ليست مناسبة للأطفال.</strong></li><li><strong>لا تستخدم تحاميل إنفلابان 12.5 ملغم لدى البالغين.</strong></li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>سوف يخبرك طبيبك عن الكمية التي يجب أن تأخذها من تحاميل إنفلابان وبوقت أخذها. اتبع دائما إرشاداته أو إرشاداتها بحذر. وسوف تكون الجرعة على ملصق الصيدلي. تحقق من الملصق بعناية. اسأل طبيبك أو الصيدلي إذا كنت غير متأكد. يجب الاستمرار في استخدام التحاميل للمدة الزمنية التي أخبرك بها الطبيب إلا إذا كانت لديك أية مشاكل. في تلك الحالة، راجع طبيبك.</p><p>إن التحاميل مصممة من أجل إدخالها في فتحة الشرج (المستقيم).</p><p><strong>لا تأخذها أبدا عن طريق الفم. </strong></p><p>قد يقوم الطبيب أيضا بوصف دواء آخر من أجل حماية المعدة يتم أخذه خلال فترة تناولك إنفلابان، بالأخص إذا كانت لديك سابقا مشاكل في المعدة، أو إذا كنت من كبار السن أو إذا كنت تتناول بعض الأدوية الأخرى.</p><p><strong>البالغين </strong></p><p>يتم إدخال تحاميل إنفلابان عادة مرة أومرتين أو ثلاث مرات في اليوم وبحد أقصى 150 ملغم لمجموع الجرعة اليومية. سوف يعتمد عدد التحاميل التي تأخذها على التركيز الذي وصفه لك الطبيب.</p><p><strong>المسنين</strong></p><p>إذا كنت كبير السن، قد ينصحك طبيبك بتناول جرعة أقل من جرعة البالغين المعتادة. وقد يريد طبيبك أيضا التحقق عن كثب من أن تحاميل إنفلابان لا تؤثر على معدتك، بالأخص خلال أول 4 أسابيع التي تستخدم فيها التحاميل.</p><p><strong>الأطفال</strong></p><p><strong>من أجل علاج التهاب المفاصل اليفعي المزمن لدى الأطفال الذين تتراوح أعمارهم من 1-12 سنة:</strong></p><p>تختلف الجرعات مع العمر، ولكن عادة ما تكون بين 1 و 3 ملغم / كغم من وزن الجسم يوميا مقسمة على 2 أو 3 جرعات.</p><p><strong>من أجل علاج الألم بعد العمليات الجراحية لدى الأطفال في سن 6 سنوات وأكثر:</strong></p><p>تختلف الجرعات مع العمر، ولكن عادة ما تكون بين 1 و 2 ملغم / كغم من وزن الجسم في كل يوم مقسمة على 2 أو 3 جرعات لمدة لا تتجاوز 4 أيام. سوف يحسب طبيب طفلك الجرعة المناسبة وسوف يخبرك بكمية و عدد مرات استخدام تحاميل إنفلابان. اتبع دائما إرشاداته أو إرشاداتها بحذر. راجع طبيبك أو الصيدلي إذا كنت غير متأكد.</p><p><strong>كيفية إدخال التحاميل</strong></p><p>1. أفرغ أمعاءك قبل إدخال التحميلة.</p><p>2. اغسل يديك.</p><p>3. أخرج شريط التحاميل وقم بفصل واحدة على طول الثقب.</p><p>4. ثم أخرج التحميلة من الغلاف البلاستيكي من خلال سحب الطرف السائب.</p><p><img alt="" width="255" height="141" src="data:image/png;base64,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" /></p><p>5. استلقي على جانب واحد وارفع ركبتيك نحو صدرك.</p><p>6. أدخل الطرف المدبب للتحميلة برفق في فتحة شرجك (المستقيم) باستخدام إصبعك. ادفع التحميلة إلى أقصى حد ممكن كما هو مبين في الرسم البياني.</p><p><img alt="" width="255" height="141" src="data:image/png;base64,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" /></p><p>7. اخفض ساقيك، إذا أمكن، وابق كذلك لبضع دقائق.<br />8. إذا كنت تشعر كما لو كنت بحاجة لدفع التحميلة خارجا، حاول مقاومة ذلك عن طريق البقاء في وضع الاستلقاء مع ضغط الإليتين معا. أنه من الضروري إبقاء التحميلة في المستقيم لإذابتها وامتصاص الدواء. إن دفع التحميلة إلى أعلى المستقيم بإصبعك يساعد على تقليل هذا الشعور.</p><p>9. اغسل يديك.</p><p>إن الإجراء هو نفسه بالنسبة للأطفال. بمجرد إفراغ أمعائهم، وحملهم على الاستلقاء على الجبهة أو على الجانب. ادفع التحميلة برفق في فتحة شرج الطفل حتى تختفي تماما. حاول منع الطفل من التحرك لبضع دقائق من أجل تقليل خطر خروج التحميلة.</p><p><strong>الجرعة الزائدة من إنفلابان </strong></p><p>يجب أن لا تأخذ أكثر من 150 ملغم في اليوم الواحد إذا كنت بالغا. يجب أن لا يأخذ الأطفال أكثر من الجرعة التي يصفها الطبيب. إذا استخدمت عن طريق الخطأ الكثير من التحاميل أو استخدمتها في كثير من الأحيان، أخبر طبيبك أو اذهب إلى أقرب قسم طوارئ على الفور.</p><p><strong>نسيان تناول تحميلة إنفلابان</strong></p><p>إذا نسيت استخدام تحميلة، لا تقلق. استخدم واحدة حالما تتذكر. إذا كان الوقت قريبا من أخذ الجرعة التالية، خذ فقط الجرعة التالية وانس الجرعة التي فاتتك. لا تضاعف الجرعة التالية لتعويض الجرعة التي فاتتك. لا تدخل تحميلتين في نفس الوقت. يجب أن لا يكون مجموع الجرعة اليومية أكثر من 150 ملغم إذا كنت بالغا.</p><p><strong>يجب أن لا يأخذ الأطفال أكثر من الجرعة التي يصفها الطبيب.</strong></p><p>إذا كان لديك أية أسئلة أخرى عن استخدام هذا المنتج الدوائي، اسأل طبيبك أو مقدم الرعاية الصحية أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>تناسب تحاميل إنفلابان معظم الناس لكن مثل جميع الأدوية، قد تتسبب في أعراض جانبية.</p><p><strong>قد تكون بعض الأعراض خطيرة</strong></p><p><strong>توقف عن استخدام أنفلابان وأخبر طبيبك فورا إذا لاحظت: </strong></p><ul><li>ألم في المعدة، عسر الهضم، وحرقة في المعدة، والغازات، والغثيان (الشعور بالمرض) أو التقيؤ (أن تكون مريضا).</li><li>أي علامة نزف في المعدة أو الأمعاء، على سبيل المثال، عند إفراغ أمعائك، والدم في القيء أو البراز القطراني أو الأسود.</li><li>ردود الفعل التحسسية التي يمكن أن تشمل الطفح الجلدي، والحكة، والكدمات، والمناطق الحمراء المؤلمة، والتقشير أو التقرحات.</li><li>الأزيز أو ضيق في التنفس (تشنج قصبي).</li><li>تورم الوجه، والشفاه، واليدين أو الأصابع.</li><li>اصفرار جلدك أو بياض عينيك.</li><li>التهاب الحلق المستمر أو ارتفاع في درجة الحرارة.</li><li>تغير&nbsp;غير متوقع في كمية البول المنتج و / أو مظهره.</li></ul><p><strong>إذا لاحظت أنك أكثر عرضة للكدمات من المعتاد أو لديك تكرار في احتقان الحلق أو العدوى، أخبر طبيبك. </strong></p><p>قد تسبب تحاميل إنفلابان أحيانا الحكة أو حرقة في فتحة الشرج أو تجعل أي بواسير أسوأ.</p><p><strong>تم أيضا الإبلاغ عن الأعراض الجانبية المدرجة أدناه </strong></p><p><strong>الآثار الجانبية الشائعة (تؤثر في 1-10 من كل 100 مريض): </strong></p><ul><li>ألم في المعدة، وحرقة في المعدة، والغثيان، والتقيؤ، والإسهال، وعسر الهضم، والغازات، وفقدان الشهية.</li><li>الصداع، والدوخة، والدوار.</li><li>الطفح الجلدي أو البقع.</li><li>ارتفاع&nbsp;مستويات أنزيمات الكبد في الدم.</li><li>تهيج مكان إدخال التحميلة.</li></ul><p><strong>الآثار الجانبية النادرة (تؤثر في مريض واحد بين 1000-10000):</strong></p><ul><li dir="rtl">قرحة أو نزف في المعدة (تم الإبلاغ عن حالات نادرة جدا أدت إلى الوفاة، وخاصة لدى كبار السن)</li><li dir="rtl">التهاب المعدة (التهاب، وتهيج أو تورم في بطانة المعدة)</li><li dir="rtl">تقيؤ الدم</li><li dir="rtl">الإسهال مع الدم فيه، أو نزيف من فتحة الشرج</li><li dir="rtl">البراز الأسود أو القطراني</li><li dir="rtl">النعاس، والتعب</li><li dir="rtl">انخفاض ضغط الدم (ضغط الدم المنخفض، وأعراضه قد تشمل الضعف، والدوخة أو الدوار الخفيف)</li><li dir="rtl">الطفح الجلدي والحكة</li><li dir="rtl">احتباس السوائل، والأعراض تشمل تورم الكاحلين</li><li dir="rtl">اضطرابات وظائف الكبد، التي تشمل التهاب الكبد واليرقان</li></ul><p><strong>الآثار الجانبية النادرة جدا (تؤثر في أقل من مريض واحد بين 10000): </strong></p><p><strong>الآثار الجانبية على الجهاز العصبي: </strong></p><p>وخز أو خدر في الأصابع، والرعاش، والاضطرابات البصرية مثل عدم وضوح الرؤية، رؤية مغيمة أو مزدوجة، وفقدان أو ضعف السمع، الطنين (رنين في الأذنين)، والأرق، والكوابيس، وتغيرات في المزاج، والاكتئاب، والقلق والاضطرابات النفسية والتوهان و فقدان الذاكرة، والنوبات المفاجئة، والصداع المقترن بكراهية الأضواء الساطعة، والحمى، وتصلب الرقبة، واضطرابات في الإحساس.</p><p><strong>الآثار الجانبية على المعدة والجهاز الهضمي: </strong></p><p>الإمساك، والتهاب اللسان، وتقرحات الفم، والتهاب داخل الفم أو الشفتين، وتغيرات في حاسة الذوق، واضطرابات القناة الهضمية السفلى (بما في ذلك التهاب القولون أو تفاقم التهاب القولون التقرحي أو مرض كرون).</p><p><strong>الآثار الجانبية على القلب والصدر والدم: </strong></p><p>خفقان القلب (ضربات القلب السريعة أو غير المنتظمة)، وألم في الصدر وارتفاع ضغط الدم (ضغط الدم المرتفع)، والتهاب الأوعية الدموية (التهاب الأوعية)، والتهاب الرئة (التهاب رئوي) واضطرابات القلب، بما في ذلك فشل القلب الاحتقاني أو النوبة القلبية، واضطرابات الدم (بما في ذلك فقر الدم).</p><p><strong>الآثار الجانبية على الكبد أو الكلى: </strong></p><p>اضطرابات الكلى أو الكبد الحادة بما في ذلك فشل الكبد ووجود الدم أو البروتين في البول.</p><p><strong>الآثار الجانبية على الجلد أو الشعر: </strong></p><p>الطفح الجلدي الخطير بما في ذلك متلازمة ستيفنز جونسون ومتلازمة لييل وأي طفح جلدي آخر قد يزداد سوءا بسبب التعرض لأشعة الشمس.</p><p>فقدان الشعر.</p><p><strong>الآثار الجانبية الأخرى التي تم الإبلاغ عنها أيضا ما يلي:</strong><br />التهاب البنكرياس، والعجز الجنسي. تورم في الوجه، والتهاب بطانة الدماغ (التهاب السحايا)، والسكتة الدماغية، واضطرابات الحلق، والالتباس، والهلوسة، والتوعك (شعور عام بعدم الارتياح)، والتهاب أعصاب العين.</p><p><strong>لا تخف من هذه القائمة - يأخذ معظم الناس إنفلابان تحاميل من دون أي مشاكل. </strong></p><p><strong>راجع طبيبك إذا ساءت أية من هذه الآثار الجانبية أو لاحظت ظهور أية آثار جانبية غير مدرجة في هذه النشرة. قد يرغب الطبيب في إعطائك دواء آخر.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li>إحفظ هذا الدواء بعيدا عن مرأى ومتناول الأطفال.</li><li>إحفظ الدواء تحت 30&deg; مئوية، بعيدا عن الضوء.</li><li>إحفظ التحاميل في علبتها الأصلية.</li><li>لا تستخدم إنفلابان بعد تاريخ انتهاء الصلاحية المذكور على العلبة الخارجية. يشير تاريخ الانتهاء إلى اليوم الأخير من ذلك الشهر.</li><li>لا تستخدم إنفلابان إذا لاحظت علامات تلف واضحة عليه.</li><li>إذا أخبرك الطبيب بالتوقف عن أخذ التحاميل، يرجى إرجاع أي تحاميل غير مستخدمة إلى الصيدلي من أجل إتلافها. لا تتخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. سوف تساعد هذه الإجراءات في حماية البيئة.</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة في كل تحميلة 12.5، 50 أو 100 ملغم هي ديكلوفيناك الصوديوم.<br />المواد الأخرى المستخدمة في التركيبة التصنيعية هي سوبوسير ن. ب. ل. شمعي صلب و ويتبسول ه-15 دهن صلب.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right">تحاميل إنفلابان 12.5 ملغم هي ذات لون من الأبيض ضارب إلى الصفرة إلى أبيض قشدي، طوربيدية الشكل. يتم تعبئتها في رقيقة من البلاستيك الأبيض غير الشفاف مسحوبة من بولي كلوريد الفينيل / البولي ايثيلين.</p><p style="text-align:right">تحاميل إنفلابان 50 ملغم هي ذات لون من الأبيض إلى الأبيض المصفر، طوربيدية الشكل. يتم تعبئتها في رقيقة من البلاستيك الأبيض غير الشفاف مسحوبة من بولي كلوريد الفينيل / البولي ايثيلين. تحتوي كل علبة على 10 تحاميل.</p><p style="text-align:right">تحاميل إنفلابان 100 ملغم هي ذات لون من الأبيض إلى الأبيض المصفر، طوربيدية الشكل. يتم تعبئتها في رقيقة من البلاستيك الأبيض غير الشفاف مسحوبة من بولي كلوريد الفينيل / البولي ايثيلين. تحتوي كل علبة على 5 تحاميل.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>مالك رخصة التسويق والشركة المصنعة</strong></p><p>الشركة العربية لصناعة الأدوية المساهمة المحدودة</p><p>صندوق البريد: 42</p><p>السلط-الأردن<br />هاتف:2200 349 5 962 +</p><p>فاكس:2203 349 5 962+</p><p>الموقع الالكتروني:&nbsp;www.apm.com.jo</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت الموافقة على هذه النشرة بتاريخ 2014/05، رقم النسخة: ن 1.1
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Infla-ban® 12.5mg Suppositories
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each suppository contains 12.5mg diclofenac sodium.

For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Off-white to creamy white, torpedo shape suppositories.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <ul><li>Children (aged 1-12 years):</li></ul><p>Juvenile chronic arthritis</p><ul><li>Children (aged 6 years and above)</li></ul><p>As monotherapy or as adjunct therapy with morphine or other opiates (due to its opiate-sparing effect) for the relief of acute post-operative pain.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.4 Special warnings and precautions for use).</p><p>Not to be taken by mouth, as per rectal administration only.</p><p>The suppositories should be inserted well into the rectum. It is recommended to insert the suppositories after passing stools.</p><p>Special populations</p><ul><li>Elderly</li></ul><p>Although the pharmacokinetics of Infla-ban are not impaired to any clinically relevant extent in elderly patients, nonsteroidal anti-inflammatory drugs should be used with particular caution in such patients who generally are more prone to adverse reactions. In particular it is recommended that the lowest effective dosage be used in frail elderly patients or those with a low body weight (see also Precautions) and the patient should be monitored for GI bleeding during NSAID therapy.</p><ul><li>Renal impairment</li></ul><p>Diclofenac is contraindicated in patients with severe renal impairment (see section 4.3). No specific studies have been carried out in patients with renal impairment, therefore, no specific dose adjustment recommendations can be made. Caution is advised when administering diclofenac to patients with mild to moderate renal impairment (see section 4.3 and 4.4).</p><ul><li>Hepatic impairment</li></ul><p>Diclofenac is contraindicated in patients with severe hepatic impairment (see section 4.3). No specific studies have been carried out in patients with hepatic impairment, therefore, no specific dose adjustment recommendations can be made. Caution is advised when administering diclofenac to patients with mild to moderate hepatic impairment (see section 4.3 and 4.4).</p><ul><li>Paediatric population</li></ul><p>- Children (aged 1-12 years) with juvenile chronic arthritis&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1-3mg/kg per day in divided doses.</p><p>&nbsp;</p><p>- Children (aged 6-12 years) with acute post-operative pain&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1-2mg/kg per day in divided doses.</p><p>&nbsp;</p><p>Treatment of acute post-operative pain should be limited to 4 days treatment&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to the active substance or any of the excipients. 
•	Active, gastric or intestinal ulcer, bleeding or perforation 
•	History of gastrointestinal bleeding or perforation, relating to previous NSAID therapy 
•	Active, or history of recurrent peptic ulcer/haemorrhage (two or more distinct episodes of proven ulceration or bleeding) 
•	Last trimester of pregnancy (see section 4.6 Pregnancy and lactation) 
•	Severe hepatic, renal or cardiac failure (see section 4.4 Special warnings and precautions for use). 
•	Like other non-steroidal anti-inflammatory drugs (NSAIDs), diclofenac is also contraindicated in patients in whom attacks of asthma, angioedema, urticaria or acute rhinitis are precipitated by ibuprofen, acetylsalicylic acid or other nonsteroidal anti-inflammatory drugs. 
•	Proctitis 
•	Established congestive heart failure (NYHA II-IV), ischemic heart disease, peripheral arterial disease and/or cerebrovascular disease. 

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <ul><li>General</li></ul><p>Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.2 Posology and method of administration and GI and cardiovascular risks below).</p><p>The concomitant use of Infla-ban with systemic NSAIDs including cyclooxygenase-2 selective inhibitors should be avoided due to the absence of any evidence demonstrating synergistic benefits and the potential for additive undesirable effects (see section 4.5 Interactions with other medicaments and other forms of interaction).</p><p>Caution is indicated in the elderly on basic medical grounds. In particular, it is recommended that the lowest effective dose be used in frail elderly patients or those with a low body weight (see section 4.2 Posology and Method of administration).</p><p>As with other nonsteroidal anti-inflammatory drugs including diclofenac, allergic reactions, including anaphylactic/anaphylactoid reactions, can also occur without earlier exposure to the drug (see section 4.8 Undesirable effects).</p><p>Like other NSAIDs, diclofenac may mask the signs and symptoms of the infection due to its pharmacodynamic properties.</p><ul><li>Gastrointestinal effects</li></ul><p>Gastrointestinal bleeding (haematemesis, melaena) ulceration or perforation which can be fatal has been reported with all NSAIDs including diclofenac and may occur at any time during treatment, with or without warning symptoms or a previous history of serious GI events. They generally have more serious consequences in the elderly. If gastrointestinal bleeding or ulceration occurs in patients receiving diclofenac, the drug should be withdrawn.</p><p>As with all NSAIDs, including diclofenac, close medical surveillance is imperative and particular caution should be excised when prescribing diclofenac in patients with symptoms indicative of gastrointestinal disorders, or with a history suggestive of gastric or intestinal ulceration, bleeding or perforation (see section 4.8 Undesirable effects). The risk of GI bleeding, ulceration or perforation is higher with increasing NSAID doses including diclofenac, and in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation.</p><p>The elderly have increased frequency of adverse reactions to NSAIDs especially gastrointestinal bleeding and perforation which may be fatal (see section 4.2 Posology and method of administration).</p><p>To reduce the risk of GI toxicity in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation, and in the elderly, the treatment should be initiated and maintained at the lowest effective dose.</p><p>Combination therapy with protective agents (e.g. misoprostol or proton pump inhibitors) should be considered for these patients, and also for patients requiring concomitant use of medicinal products containing low dose acetylsalicylic acid (ASA/aspirin or medicinal products likely to increase gastrointestinal risk. (See section 4.5 Interactions with other medicaments and other forms of interaction).</p><p>Patients with a history of GI toxicity, particularly when elderly, should report any unusual abdominal symptoms (especially GI bleeding).</p><p>Caution is recommended in patients receiving concomitant medications which could increase the risk of ulceration or bleeding, such as systemic corticosteroids, anticoagulants such as warfarin, selective serotonin-reuptake inhibitors (SSRIs) or antiplatelet agents such as acetylsalicylic acid (see section 4.5 Interaction with other medicaments and other forms of interaction).</p><p>Close medical surveillance and caution should be exercised in patients with ulcerative colitis, or with Crohn&#39;s disease as these conditions may be exacerbated (see section 4.8 Undesirable effects).</p><ul><li>Hepatic effects</li></ul><p>Close medical surveillance is required when prescribing Infla-ban to patients with impairment of hepatic function as their condition may be exacerbated.</p><p>As with other NSAIDs, including diclofenac, values of one or more liver enzymes may increase. During prolonged treatment with Diclofenac, regular monitoring of hepatic function is indicated as a precautionary measure.</p><p>If abnormal liver function tests persist or worsen, clinical signs or symptoms consistent with liver disease develop or if other manifestations occur (eosinophilia, rash), Infla-ban should be discontinued.</p><p>Hepatitis may occur with diclofenac without prodromal symptoms.</p><p>Caution is called for when using diclofenac in patients with hepatic porphyria, since it may trigger an attack.</p><ul><li>Renal effects</li></ul><p>As fluid retention and oedema have been reported in association with NSAIDs therapy, including diclofenac, particular caution is called for in patients with impaired cardiac or renal function, history of hypertension, the elderly, patients receiving concomitant treatment with diuretics or medicinal products that can significantly impact renal function, and those patients with substantial extracellular volume depletion from any cause, e.g. before or after major surgery (see section 4.3 Contraindications). Monitoring of renal function is recommended as a precautionary measure when using diclofenac in such cases. Discontinuation therapy is usually followed by recovery to the pre-treatment state.</p><ul><li>Skin effects</li></ul><p>Serious skin reactions, some of them fatal, including exfoliative dermatitis, StevensJohnson syndrome and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs, including Infla-ban (see section 4.8 Undesirable effects). Patients appear to be at the highest risk of these reactions early in the course of therapy: the onset of the reaction occurring in the majority of cases within the first month of treatment. Infla-ban should be discontinued at the first appearance of skin rash, mucosal lesions or any other signs of hypersensitivity.</p><ul><li>SLE and mixed connective tissue disease</li></ul><p>In patients with systemic lupus erythematosus (SLE) and mixed connective tissue disorders there may be an increased risk of aseptic meningitis (see section 4.8 Undesirable effects).</p><ul><li>Cardiovascular and cerebrovascular effects</li></ul><p>Patients with significant risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking) should only be treated with diclofenac after careful consideration. As the cardiovascular risks of diclofenac may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. The patient&#39;s need for symptomatic relief and response to therapy should be re-evaluated periodically.&nbsp;</p><p>Appropriate monitoring and advice are required for patients with a history of hypertension and/or mild to moderate congestive heart failure as fluid retention and oedema have been reported in association with NSAID therapy, including diclofenac.&nbsp;</p><p>Clinical trial and epidemiological data consistently point towards increased risk of arterial thrombotic events (for example myocardial infarction or stroke) associated with the use of diclofenac, particularly at high dose (150mg daily) and in long term treatment.&nbsp;</p><p>Patients with uncontrolled hypertension, congestive heart failure, established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease should only be treated with diclofenac after careful consideration.&nbsp;</p><ul><li>Haematological effects</li></ul><p>During prolonged treatment with diclofenac, as with other NSAIDs, monitoring of the blood count is recommended.</p><p>Infla-ban may reversibly inhibit platelet aggregation (see anticoagulants in section 4.5 Interaction with other medicaments and other forms of interactions). Patients with defects of haemostasis, bleeding diathesis or haematological abnormalities should be carefully monitored.</p><ul><li>Pre-existing asthma</li></ul><p>In patients with asthma, seasonal allergic rhinitis, swelling of the nasal mucosa (i.e. nasal polyps), chronic obstructive pulmonary diseases or chronic infections of the respiratory tract (especially if linked to allergic rhinitis-like symptoms), reactions on NSAIDs like asthma exacerbations (so called intolerance to analgesics / analgesics asthma), Quincke&#39;s oedema or urticaria are more frequent than in other patients. Therefore, special precaution is recommended in such patients (readiness for emergency). This is applicable as well for patients who are allergic to other substances, e.g. with skin reactions, pruritus or urticaria.</p><p>Like other drugs that inhibit prostaglandin synthetase activity, diclofenac sodium and other NSAIDs can precipitate bronchospasm if administered to patients suffering from, or with a previous history of bronchial asthma.</p><ul><li>Female fertility</li></ul><p>The use of Infla-ban may impair female fertility and is not recommended in women attempting to conceive. In women who may have difficulties conceiving or who are undergoing investigation of infertility, withdrawal of Infla-ban should be considered (see section 4.6 Pregnancy and Lactation).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>following interactions include those observed with diclofenac gastro-resistant tablets and/or other pharmaceutical forms of diclofenac.</p><ul><li>Lithium</li></ul><p>If used concomitantly, Infla-ban may increase plasma concentrations of lithium Monitoring of the serum lithium level is recommended.</p><ul><li>Digoxin</li></ul><p>If used concomitantly, Infla-ban may raise plasma concentrations of digoxin. Monitoring of the serum digoxin level is recommended.</p><ul><li>Diuretics and antihypertensive agents</li></ul><p>&nbsp;Like other NSAIDs, concomitant use of Infla-ban with diuretics and antihypertensive agents (e.g. beta-blockers, angiotensin converting enzyme (ACE) inhibitors may cause a decrease in their antihypertensive effect via inhibition of vasodilatory prostaglandin synthesis.<strong> </strong></p><p>Therefore, the combination should be administered with caution and patients, especially the elderly, should have their blood pressure periodically monitored. Patients should be adequately hydrated and consideration should be given to monitoring of renal function after initiation of concomitant therapy periodically thereafter, particularly for diuretics and ACE inhibitors due to the increased risk of nephrotoxicity.</p><ul><li>Drugs known to cause hyperkalemia</li></ul><p>&nbsp;Concomitant treatment with potassium-sparing diuretics, ciclosporin, tacrolimus or trimethoprim may be associated with increased serum potassium levels, which should therefore be monitored frequently (see section 4.4 Special warnings and precautions for use).</p><ul><li>Anticoagulants and anti-platelet agents</li></ul><p>Caution is recommended since concomitant administration could increase the risk of bleeding (see section 4.4 Special warnings and precautions for use). Although clinical investigations do not appear to indicate that Infla-ban has an influence on the effect of anticoagulants, there are isolated reports of an increased risk of haemorrhage in patients receiving diclofenac and anticoagulant concomitantly (see section 4.4 Special warnings and precautions for use). Therefore, to be certain that no change in anticoagulant dosage is required, close monitoring of such patients is required. As with other nonsteroidal antiinflammatory agents, diclofenac in a high dose can reversibly inhibit platelet aggregation.</p><ul><li>Other NSAIDs including cyclooxygenase-2 selective inhibitors and corticosteroids&nbsp; Co-administration of diclofenac with other systemic NSAIDs or corticosteroids may increase the risk of gastrointestinal bleeding or ulceration. Avoid concomitant use of two or more NSAIDs (see section 4.4 Special warnings and precautions for use).</li><li>Selective serotonin reuptake inhibitors (SSRIs)</li></ul><p>&nbsp;Concomitant administration of SSRI&#39;s may increase the risk of gastrointestinal bleeding (see section 4.4 Special warnings and precautions for use).</p><ul><li>Antidiabetics</li></ul><p>Clinical studies have shown that Infla-ban can be given together with oral antidiabetic agents without influencing their clinical effect. However there have been isolated reports of hypoglycaemic and hyperglycaemic effects necessitating changes in the dosage of the antidiabetic agents during treatment with diclofenac. For this reason, monitoring of the blood glucose level is recommended as a precautionary measure during concomitant therapy.</p><ul><li>Methotrexate</li></ul><p>&nbsp;Diclofenac can inhibit the tubular renal clearance of methotrexate hereby increasing methotrexate levels. Caution is recommended when NSAIDs, including diclofenac, are administered less than 24 hours before treatment with methotrexate, since blood concentrations of methotrexate may rise and the toxicity of this substance be increase. Cases of serious toxicity have been reported when methotrexate and NSAIDs including diclofenac are given within 24 hours of each other. This interaction is mediated through accumulation of methotrexate resulting from impairment of renal excretion in the presence of the NSAID.</p><ul><li>Ciclosporin</li></ul><p>&nbsp;Diclofenac, like other NSAIDs, may increase the nephrotoxicity of ciclosporin due to the effect on renal prostaglandins. Therefore, it should be given at doses lower than those that would be used in patients not receiving ciclosporin.</p><ul><li>Tacrolimus</li></ul><p>Possible increased risk of nephrotoxicity when NSAIDs are given with tacrolimus. This might be mediated through renal antiprostagladin effects of both NSAID and calcineurin inhibitor.</p><ul><li>Quinolone antibacterials</li></ul><p>&nbsp;Convulsions may occur due to an interaction between quinolones and NSAIDs. This may occur in patients with or without a previous history of epilepsy or convulsions. Therefore, caution should be exercised when considering the use of a quinolone in patients who are already receiving an NSAID.</p><ul><li>Phenytoin</li></ul><p>&nbsp;When using phenytoin concomitantly with diclofenac, monitoring of phenytoin plasma concentrations is recommended due to an expected increase in exposure to phenytoin.</p><ul><li>Colestipol and cholestyramine</li></ul><p>These agents can induce a delay or decrease in absorption of diclofenac. Therefore, it is recommended to administer diclofenac at least one hour before or 4 to 6 hours after administration of colestipol/ cholestyramine.</p><ul><li>Cardiac glycosides</li></ul><p>&nbsp;Concomitant use of cardiac glycosides and NSAIDs in patients may exacerbate cardiac failure, reduce GFR and increase plasma glycoside levels.</p><ul><li>Mifepristone</li></ul><p>NSAIDs should not be used for 8-12 days after mifepristone administration as NSAIDs can reduce the effect of mifepristone.<strong> </strong></p><ul><li>Potent CYP2C9 inhibitors</li></ul><p>Caution is recommended when co-prescribing diclofenac with potent CYP2C9 inhibitors (such as voriconazole), which could result in a significant increase in peak plasma concentrations and exposure to diclofenac due to inhibition of diclofenac metabolism.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <ul><li>Pregnancy&nbsp;</li></ul><p>Pregnancy Category C</p><p>Inhibition of prostaglandin synthesis may adversely affect the pregnancy and/or the embryo/foetal development. Data from epidemiological studies suggest an increased risk of miscarriage and or cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk for cardiovascular malformation was increased from less than 1% up to approximately 1.5%.</p><p>The risk is believed to increase with dose and duration of therapy. In animals, administration of a prostaglandin synthesis inhibitor has shown to result in increased pre-and post-implantation loss and embryo-foetal lethality.</p><p>In addition, increased incidences of various malformations, including cardiovascular, have been reported in animals given a prostaglandin synthesis inhibitor during organogenetic period. If Infla-ban is used by a woman attempting to conceive, or during the 1st trimester of pregnancy, the dose should be kept as low and duration of treatment as short as possible.</p><p>During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the foetus to:</p><p>-&nbsp; cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension)</p><p>-&nbsp; Renal dysfunction, which may progress to renal failure with oligo-hydroamniosis</p><p>The mother and the neonate, at the end of the pregnancy, to:</p><p>-&nbsp; Possible prolongation of bleeding time, an anti-aggregating effect which may occur even at very low doses</p><p>-&nbsp; inhibition of uterine contractions resulting in delayed or prolonged labour</p><p>Consequently, Infla-ban is contra-indicated during the third trimester of pregnancy.</p><ul><li>Lactation</li></ul><p>Like other NSAIDs, diclofenac passes into breast milk in small amounts. Therefore Diclofenac should not be administered during breast feeding in order to avoid undesirable effects in the infant (see section 5.2 Pharmacokinetic properties).</p><ul><li>Female fertility</li></ul><p>As with other NSAIDs, the use of diclofenac may impair female fertility and is not recommended in women attempting to conceive. In women who may have difficulties conceiving or who are undergoing investigation of infertility, withdrawal of diclofenac should be considered. See also section 4.4 Special warnings and precautions for use, regarding female fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients who experience visual disturbances, dizziness, vertigo, somnolence, central nervous system disturbances, drowsiness or fatigue while taking NSAIDs should refrain from driving or operating machinery.<strong> </strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse reactions are ranked under the heading of frequency, the most frequent first, using the following convention: very common: (&gt;1/10); common (&ge; 1/100, &lt;1/10); uncommon (&ge; 1/1,000, &lt;1/100); rare (&ge;1/10,000, &lt;1/1000); very rare (&lt;1/10,000); not known: cannot be estimated from available data.</p><p>The following undesirable effects include those reported with other short-term or longterm use.</p><p><strong>Blood and lymphatic system disorders</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:556px"><tbody><tr><td style="vertical-align:top"><p>Very rare</p><p><strong>&nbsp;</strong></p><p><strong>Immune system disorders</strong></p></td><td colspan="3" style="vertical-align:top"><p>Thrombocytopenia, leucopoenia, anaemia (including haemolytic and aplastic anaemia), agranulocytosis.</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td colspan="3" style="vertical-align:top"><p>Hypersensitivity, anaphylactic and anaphylactoid reactions (including hypotension and shock).</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p><p><strong>&nbsp;</strong></p><p><strong>Psychiatric disorders</strong></p></td><td colspan="3" style="vertical-align:top"><p>Angioneurotic oedema (including face oedema).</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p><p><strong>&nbsp;</strong></p><p><strong>Nervous system disorders</strong></p></td><td colspan="3" style="vertical-align:top"><p>Disorientation, depression, insomnia, nightmare, irritability, psychotic disorder.</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td colspan="3" style="vertical-align:top"><p>Headache, dizziness.</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td colspan="3" style="vertical-align:top"><p>Somnolence, tiredness.</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td colspan="3" style="vertical-align:top"><p>Paraesthesia, memory impairment, convulsion, anxiety, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tremor, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; aseptic &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; meningitis, &nbsp;&nbsp;&nbsp;&nbsp; taste disturbances, cerebrovascular accident.</p></td></tr><tr><td style="vertical-align:top"><p>Unknown</p><p><strong>&nbsp;</strong></p><p><strong>Eye disorders</strong></p></td><td colspan="3" style="vertical-align:top"><p>Confusion, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hallucinations, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disturbances &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of sensation, malaise.</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td colspan="3" style="vertical-align:top"><p>Visual disturbance, vision blurred, diplopia.</p></td></tr><tr><td style="vertical-align:top"><p>Unknown</p><p><strong>&nbsp;</strong></p><p><strong>Ear and labyrinth disorders</strong></p></td><td style="vertical-align:top"><p>Optic neuritis.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Vertigo.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p><p><strong>&nbsp;</strong></p><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top"><p>Tinnitus, hearing impaired.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p><p><strong>&nbsp;</strong></p><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>Palpitations, &nbsp;&nbsp; chest &nbsp;&nbsp; pain, myocardial infarction.</p></td><td style="vertical-align:top"><p>cardiac</p></td><td style="vertical-align:top"><p>failure,</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td colspan="2" style="vertical-align:top"><p>Hypertension, hypotension, vasculitis.</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:556px"><tbody><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Asthma (including dyspnoea).</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p><p><strong>&nbsp;</strong></p><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>Pneumonitis.</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Nausea, vomiting, diarrhoea, dyspepsia, abdominal pain, flatulence, anorexia.</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Gastritis, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; gastrointestinal &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; haemorrhage, haematemesis, diarrhoea haemorrhagic, melaena, gastrointestinal ulcer with or without bleeding or perforation (sometimes fatal particularly in the elderly).</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p><p><strong>&nbsp;</strong></p><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top"><p>Colitis (including haemorrhagic colitis and exacerbation of ulcerative colitis or Crohn&#39;s disease), constipation, stomatitis (including ulcerative stomatitis), glossitis, oesophageal disorder, diaphragm-like intestinal strictures, pancreatitis.</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Transaminases increased.</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Hepatitis, jaundice, liver disorder.</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Fulminant hepatitis, hepatic necrosis, hepatic failure.</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Skin and subcutaneous tissue disorders</strong></p><table border="0" cellspacing="0" cellpadding="0" style="width:556px"><tbody><tr><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Rash.</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Urticaria.</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Bullous eruptions, eczema, erythema, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (Lyell&#39;s syndrome), dermatitis exfoliative, loss of hair, photosensitivity reaction, purpura, allergic purpura, pruritus.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Renal and urinary disorders</strong></p><p>Very rare &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute renal failure, haematuria, proteinuria,</p><p>nephrotic syndrome, interstitial nephritis, renal papillary necrosis.</p><p><strong>&nbsp;</strong></p><p><strong>General disorders and administration site conditions</strong></p><p>Rare &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Application site irritation, oedema</p><p><strong>&nbsp;</strong></p><p><strong>Reproductive system and breast disorders</strong></p><p>Very rare &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Impotence</p><p>&nbsp;</p><p>Clinical trial and epidemiological data suggest that use of diclofenac, particularly at high doses (150mg daily) and in long term treatment may be associated with a small increased risk of arterial thrombotic events (for example myocardial infarction or stroke) (see section 4.4 Special warnings and special precautions for use).</p><p><strong><u>Reporting of suspected adverse reactions</u> </strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong>&nbsp;</p><p>&minus; The National Pharmacovigilance and Drug Safety Centre (NPC)&nbsp;</p><p>Fax: +966-11-205-7662&nbsp;</p><p>Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.&nbsp;</p><p>Toll free phone: 8002490000&nbsp;</p><p>E-mail: <u>npc.drug@sfda.gov.sa</u></p><p>&nbsp;Website: www.sfda.gov.sa/npc</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States:</strong> Please contact the relevant competent authority.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <ul><li>Symptoms:</li></ul><p>There is no typical clinical picture resulting from diclofenac over dosage. Over dosage can cause symptoms such as headache, nausea, vomiting, epigastric pain, gastrointestinal bleeding, diarrhoea, dizziness, disorientation, excitation, coma, drowsiness, tinnitus, fainting or convulsions. In the case of significant poisoning acute renal failure and liver damage are possible.</p><p><strong>&nbsp;</strong></p><ul><li>Therapeutic measures:</li></ul><p>Patients should be treated symptomatically as required. Within one hour of ingestion of a potentially toxic amount, activated charcoal should be considered. Alternatively, in adults gastric lavage should be considered within one hour of ingestion of potentially toxic amounts. Frequent or prolonged convulsions should be treated with intravenous diazepam. Other measures may be indicated by the patients clinical condition.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In 15 clinical studies involving the use of rectal diclofenac in the treatment of postoperative pain in children with an overall mean age of 8 years, the use of rescue analgesia (particularly opiates) was reduced.</p><ul><li>Pharmacotherapeutic group:&nbsp;</li></ul><p>Nonsteroidal anti-inflammatory drugs (NSAIDs).</p><ul><li>Mechanism of action</li></ul><p>Infla-ban is a nonsteroidal agent with marked analgesic/anti- inflammatory properties. It is an inhibitor of prostaglandin synthetase, (cyclo-oxygenase).</p><p>Diclofenac sodium in vitro does not suppress proteoglycan biosynthesis in cartilage at concentrations equivalent to the concentrations reached in human beings.</p><p>There is a limited clinical trial experience of the use of diclofenac in JRA/JIA paediatric patients. In a randomised, double-blind, 2-week, parallel group study in children aged 315 years with JRA/JIA, the efficacy and safety of daily 2-3 mg/kg BW diclofenac was compared with acetylsalicylic acid (ASS, 50-100 mg/kg BW/d) and placebo &ndash; 15 patients in each group. In the global evaluation, 11 of 15 diclofenac patients, 6 of 12 aspirin and 4 of 15 placebo patients showed improvement with the difference being statistically significant (p &lt;0.05). The number of tender joints decreased with diclofenac and ASS but increased with placebo. In a second randomised, double-blind, 6 week, parallel group study in children aged 4-15 years with JRA/JIA, the efficacy of diclofenac (daily dose 2-3 mg/kg BW, n=22) was comparable with that of indomethacin (daily dose 2-3 mg/kg BW, (n=23).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is limited kinetic data from 6 children aged 6-16 years with juvenile chronic arthritis who received a once daily dose of diclofenac for 2 weeks. When corrected for a body weight of 75kg, kinetic parameters were similar to those in adults.</p><ul><li>Absorption</li></ul><p>Absorption is rapid; although the rate of absorption is slower than from enteric-coated tablets administered orally. After the administration of 50mg suppositories, peak plasma concentrations are attained on average within 1 hour, but maximum concentrations per dose unit are about two thirds of those reached after administration of enteric-coated tablets (1.95 &plusmn; 0.8&micro;g/ml (1.9&micro;g/ml &equiv; 5.9&micro;mol/l)).</p><ul><li>Bioavailability</li></ul><p>As with oral preparations the AUC is approximately a half of the value obtained from a parenteral dose.</p><p>Pharmacokinetic behaviour does not change on repeated administration. Accumulation does not occur, provided the recommended dosage intervals are observed.</p><p>The plasma concentrations attained in children given equivalent doses (mg/kg, b.w.) are similar to those obtained in adults.&nbsp;</p><ul><li>Distribution</li></ul><p>The active substance is 99.7% protein bound, mainly to albumin (99.4%).</p><p>Diclofenac enters the synovial fluid, where maximum concentrations are measured 2-4 hours after the peak plasma values have been attained. The apparent half-life for elimination from the synovial fluid is 3-6 hours. Two hours after reaching the peak plasma values, concentrations of the active substance are already higher in the synovial fluid than they are in the plasma and remain higher for up to 12 hours.</p><p>Diclofenac was detected in a low concentration (100 ng/mL) in breast milk in one nursing mother. The estimated amount ingested by an infant consuming breast milk is equivalent to a 0.03 mg/kg/day dose (see section 4.6 Pregnancy and lactation).</p><ul><li>Metabolism</li></ul><p>Biotransformation of diclofenac takes place partly by glucuronidation of the intact molecule, but mainly by single and multiple hydroxylation and methoxylation, resulting in several phenolic metabolites , most of which are converted to glucuronide conjugates. Two phenolic metabolites are biologically active, but to a much lesser extent than diclofenac.</p><ul><li>Elimination</li></ul><p>The total systemic clearance of diclofenac in plasma is 263 &plusmn; 56 mL/min (mean value &plusmn; SD). The terminal half-life in plasma is 1-2 hours. Four of the metabolites, including the two active ones, also have short plasma half-lives of 1-3 hours.</p><p>About 60% of the administered dose is excreted in the urine in the form of the glucuronide conjugate of the intact molecule and as metabolites, most of which are also converted to glucuronide conjugates. Less than 1% is excreted as unchanged substance. The rest of the dose is eliminated as metabolites through the bile in the faeces.</p><ul><li>Characteristics in patients</li></ul><p>No relevant age-dependent differences in the drug&#39;s absorption, metabolism, or excretion have been observed, other than the finding that in five elderly patients, a 15 minute iv infusion resulted in 50% higher plasma concentrations than expected with young healthy subjects.</p><ul><li>Patients with renal impairment</li></ul><p>&nbsp;In patients suffering from renal impairment, no accumulation of the unchanged active substance can be inferred from the single-dose kinetics when applying the usual dosage schedule. At a creatinine clearance of less than 10 mL/min, the calculated steady-state plasma levels of the hydroxy metabolites are about 4 times higher than in normal subjects. However, the metabolites are ultimately cleared through the bile.</p><ul><li>Patients with hepatic disease</li></ul><p>&nbsp;In patients with chronic hepatitis or non-decompensated cirrhosis, the kinetics and metabolism of diclofenac are the same as in patients without liver disease.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no per clinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>-&nbsp;&nbsp;&nbsp; Suppocire NBL waxy solid</p><p>-&nbsp;&nbsp;&nbsp; Witepsol H-15 hard fat</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C, away from light.</p><p>Medicines should be kept out of the reach of children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Opaque white plastic laminated PVC/PE foil.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For rectal use only.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 The Arab Pharmaceutical Manufacturing Co. Ltd. (APM)
  P.O.Box 42 
 Sult - Jordan

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                11 May 2014 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>